EGFR and head and neck squamous cell carcinoma: Cetuximab, a monoclonal antibody targeting the extracellular ligand binding domain of the epidermal growth factor receptor (EGFR), is approved for the treatment of locoregionally advanced HNSCC in combination with radiotherapy [9] and for the treatment of recurrent or metastatic disease in combination with platinum-based chemotherapy [7].